Decompensated Cirrhosis: Resources for Diagnosis and Management of Clinical Manifestations and Comorbidities
Decompensated Cirrhosis
Resources for Diagnosis and Management of Clinical Manifestations and Comorbidities
This resource center is supported by an educational grant from Mallinckrodt Pharmaceuticals.
This resource center is designed to give physicians and other health care providers a comprehensive overview of decompensated cirrhosis so that they will better understand how to manage the clinical manifestations and comorbidities of this condition.
Approximately 4.5 million adults in the United States are living with chronic liver disease, representing 1.8% of the population. Cirrhosis is a result of longstanding fibrosis and can result in various negative sequelae, including gastrointestinal hemorrhage, hepatic encephalopathy, ascites, renal failure, and hepatocellular carcinoma. Hepatorenal syndrome (HRS) is a unique form of acute kidney injury (AKI) that develops as an end-stage complication of cirrhosis. The prognosis of HRS-AKI is poor and associated with high mortality, increased lengths of hospital stay, and higher costs of hospitalizations compared with cirrhosis without HRS. Esophageal variceal rupture is the most common fatal complication of cirrhosis; the severity of liver disease correlates with the presence of varices and risk of bleeding. Ascites is the most common complication related to cirrhosis and is associated with increased morbidity and mortality. Refractory ascites occurs in approximately 5% to 10% of all patients with cirrhosis and ascites and is associated with survival of only 50% at 6 months.
Activity Curriculum
-
Clinical Consultations™: Facilitating Optimal Treatment Outcomes and Multidisciplinary Care in Hepatorenal Syndrome- Acute Kidney Injury (HRS-AKI)
Define the criteria used to diagnose hepatorenal syndrome of acute kidney injury.
-
Advances In™ Cirrhosis: Reframing the Management of Hepatorenal Syndrome-Acute Kidney Injury: A Review of Current Strategies
Recognize the complex pathology of HRS-AKI and emerging approaches intended to intervene in disease progression
-
Burst Expert Illustrations & Commentaries™: Management Strategies for Refractory Ascites
Formulate a treatment plan for patients with refractory ascites based on current evidence
-
Burst Expert Illustrations & Commentaries™: Current Treatments for Esophageal Variceal Hemorrhage
Apply current evidence to the selection of treatment measures for the management of variceal bleeding
-
Release Date: June 20, 2022
Expiration Date: June 20, 2023
Est. Activity Time: 180 minutes total for all 4 activities
Acknowledgment of Commercial Support
This resource center is supported by an educational grant from Mallinckrodt Pharmaceuticals.
Faculty, Staff, and Planners’ Disclosures
The staff of Physicians’ Education Resource®, LLC, have no relevant financial relationships with ineligible companies.
PER® mitigated all COI for faculty, staff, and planners prior to the start of this activity by using a multistep process.
Off-Label Disclosure and Disclaimer
This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a healthcare professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or any company that provided commercial support for this activity.